First HER2 directed therapy to show an improvement in overall survival for previously-treated metastatic gastric cancer with a 41% reduction in the risk of death versus chemotherapy Breakthrough Therapy Designation recently granted in the U.S. for ENHERTU in this setting Detailed results from the positive pivotal randomized, controlled phase 2 DESTINY-Gastric01 trial showed Daiichi Sankyo […]
Read MoreAutor: Firma DAIICHI SANKYO EUROPE
ENHERTU® Achieved a Tumor Response Rate of 45.3% in Patients with HER2 Positive Metastatic Colorectal Cancer in Phase 2 DESTINY-CRC01 Trial
Results from the phase 2 DESTINY-CRC01 trial of Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and AstraZeneca’s ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated clinically meaningful activity in patients with HER2 positive unresectable and/or metastatic colorectal cancer who received at least two prior lines of standard treatment. These results were presented today at the 2020 American Society of Clinical […]
Read MoreENHERTU® Demonstrated Meaningful Clinical Activity in Patients with HER2 Mutant Non-Small Cell Lung Cancer in Interim Analysis of Phase 2 DESTINY-Lung01 Trial
9% of patients with HER2 mutant metastatic non-small cell lung cancer treated with ENHERTU achieved a tumor response Breakthrough Therapy Designation recently granted in the U.S. in this setting Results from the ongoing phase 2 DESTINY-Lung01 trial showed Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and AstraZeneca’s ENHERTU® (fam-trastuzumab deruxtecan-nxki) achieved a clinically meaningful tumor […]
Read More